Madison Asset Management LLC Buys New Position in Armata Pharmaceuticals, Inc. $ARMP

Key Points

• Madison Asset Management acquired 2.11 million Armata Pharmaceuticals shares worth approximately $13.65 million, giving it a 5.74% stake. Other institutions, including BlackRock, also initiated or increased positions, though institutional ownership remains modest at 3.57%.
• Armata shares opened at $5.07, well below their 52-week high of $16.34, with the stock’s 200-day moving average at $8.08. The company reported a quarterly loss of $0.27 per share, beating estimates, and revenue of $2.51 million versus expectations of $0.40 million.
• Analysts maintain a “Moderate Buy” consensus, supported by two Buy ratings and one Hold rating, with an average price target of $15. Armata is developing bacteriophage therapies targeting antibiotic-resistant infections.

Madison Asset Management LLC purchased a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,107,175 shares of the company's stock, valued at approximately $13,654,000. Madison Asset Management LLC owned about 5.74% of Armata Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ARMP. BlackRock Inc. purchased a new stake in shares of Armata Pharmaceuticals during the second quarter worth about $3,629,000. Deutsche Bank AG acquired a new stake in Armata Pharmaceuticals in the 2nd quarter worth approximately $78,000. Bank of New York Mellon Corp acquired a new stake in Armata Pharmaceuticals in the 2nd quarter worth approximately $193,000. Bank of America Corp DE boosted its stake in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company's stock worth $120,000 after purchasing an additional 8,198 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in Armata Pharmaceuticals during the 1st quarter worth approximately $760,000. Institutional investors and hedge funds own 3.57% of the company's stock.

Armata Pharmaceuticals Stock Performance

Shares of ARMP opened at $5.07 on Thursday. The stock has a 50-day moving average of $5.41 and a two-hundred day moving average of $8.08. Armata Pharmaceuticals, Inc. has a one year low of $2.40 and a one year high of $16.34. The stock has a market cap of $188.50 million, a P/E ratio of -0.67 and a beta of 1.30.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.17. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%.The business had revenue of $2.51 million for the quarter, compared to analyst estimates of $0.40 million. Analysts predict that Armata Pharmaceuticals, Inc. will post 0.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a "hold" rating in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

Want to see what other hedge funds are holding ARMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source